Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 12/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.36 |
| ▸ | PIM1 | P11309 | 2/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL861193 | 1.00 | SMPD3 (0.51) | SMPD3IRAK4PIM1PIM2 | |
| SCHEMBL12979110 | 1.00 | SMPD3 (0.51) | SMPD3IRAK4PIM1PIM2 | |
| SCHEMBL12979070 | 0.90 | SMPD3 (0.42) | SMPD3IRAK4 | |
| SCHEMBL851080 | 0.90 | SMPD3 (0.42) | SMPD3IRAK4 | |
| SCHEMBL851079 | 0.90 | SMPD3 (0.42) | SMPD3IRAK4 | |
| SCHEMBL12978970 | 0.79 | CGAS (0.38) | PIM1 | |
| SCHEMBL860137 | 0.79 | CGAS (0.38) | PIM1 | |
| SCHEMBL860136 | 0.79 | CGAS (0.38) | PIM1 | |
| SCHEMBL20015989 | 0.78 | SMPD3 (0.63) | SMPD3IRAK4PIM1PIM2 | |
| SCHEMBL20015889 | 0.77 | SMPD3 (0.62) | SMPD3IRAK4PIM1PIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367681-B2 | Pyrazolopyrimidines and related heterocycles as kinase inhibitors | CYLENE PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| EP-2432473-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | Cylene Pharmaceuticals, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | SENHWA BIOSCIENCES, INC. (TW) | 2010-12-30 | — | — | US | disclosed |
| WO-2010135581-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331314-A1 | PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS | PIM1, PIM2, PIM3 | SMPD3 4539/4885IRAK4 112/4885PIM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.